Skip to content
← Full study record

NCT00638690 · MORE INFO

Limitations, agreements, and source contact

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy · Source last updated 2014-04-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. After 1) publication of multi-center results, 2) notification by sponsor that a multi-center submission is no longer planned, or 3) the 18 month anniversary of the termination of the study at all sites, the institution and investigator may publish or publicly present study data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Johnson & Johnson Pharmaceutical Research & Development
phone
310-914-2915
title
Senior Director, Clinical Research
Complete source fields
certain Agreement
other Details
The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. After 1) publication of multi-center results, 2) notification by sponsor that a multi-center submission is no longer planned, or 3) the 18 month anniversary of the termination of the study at all sites, the institution and investigator may publish or publicly present study data.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Johnson & Johnson Pharmaceutical Research & Development
phone
310-914-2915
title
Senior Director, Clinical Research

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice